Jazz Pharmaceuticals
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 6 disclosed transactions, Jazz Pharmaceuticals concentrates its licensing activity in Oncology, Neurology, and Mega Deals. Jazz Pharmaceuticals pays a 1.33x premium over market median. Their most common deal structure is Acquisition, with an average disclosed value of $3.2B. Most recent activity: 2026.
Pipeline coverage & gaps
Jazz Pharmaceuticals has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 3 | $3.2B | $3.4B |
| Collaboration | 2 | — | $4.0B |
| License | 1 | $43M | $1.0B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | T cell engagers program | AbCellera Biologics | — | unknown | — | $4.0B |
| 2026 | T cell engager discovery and development program | AbCellera | oncology / immunology | discovery | — | $4.0B |
| 2025 | SAN2355 | Saniona | Epilepsy | preclinical | $43M | $1.0B |
| 2025 | dordaviprone | Chimerix | H3 K27M-mutant glioma (rare brain tumors) | phase_3 | $935M | $935M |
| 2022 | Zanidatamab | Zymeworks | Gastric, Biliary tract, Colorectal | phase_3 | $1.4B | $2.0B |
| 2020 | epilepsy | GW Pharmaceuticals | epilepsy | approved | $7.2B | $7.2B |
How this is computed
For each Jazz Pharmaceuticals deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 1.331, clamped to [0.7, 1.5].